Bank of New York Mellon Corp Invests $1.02 Million in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Bank of New York Mellon Corp acquired a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 454,464 shares of the company’s stock, valued at approximately $1,018,000.

A number of other large investors have also added to or reduced their stakes in TSHA. Victory Capital Management Inc. acquired a new position in Taysha Gene Therapies in the 4th quarter valued at approximately $28,000. Dynamic Technology Lab Private Ltd bought a new position in Taysha Gene Therapies during the 4th quarter worth $31,000. Cannon Global Investment Management LLC bought a new position in Taysha Gene Therapies during the 1st quarter worth $69,000. China Universal Asset Management Co. Ltd. grew its position in shares of Taysha Gene Therapies by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company’s stock valued at $103,000 after buying an additional 14,286 shares during the last quarter. Finally, Chicago Partners Investment Group LLC raised its position in shares of Taysha Gene Therapies by 21.4% during the fourth quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company’s stock worth $239,000 after acquiring an additional 23,740 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA opened at $2.15 on Friday. The firm has a market capitalization of $440.62 million, a P/E ratio of -4.39 and a beta of 0.41. The firm’s 50-day moving average price is $2.20 and its 200-day moving average price is $2.59. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.35. Taysha Gene Therapies, Inc. has a 1-year low of $1.27 and a 1-year high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The business had revenue of $1.11 million during the quarter, compared to analyst estimates of $3.62 million. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. During the same period in the previous year, the company posted ($0.38) EPS. Equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder Paul B. Manning bought 1,333,333 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The shares were bought at an average cost of $2.25 per share, for a total transaction of $2,999,999.25. Following the acquisition, the insider now directly owns 1,333,333 shares in the company, valued at $2,999,999.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.70% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on TSHA. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Piper Sandler cut their price target on shares of Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating on the stock in a research report on Monday, July 1st. Canaccord Genuity Group decreased their price target on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. JMP Securities reissued a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Finally, Needham & Company LLC decreased their target price on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $6.38.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.